Email this article 
Hide
Show all
Impact of adverse events of antiretroviral treatment on regimen change and mortality in Ugandan children
Abstract
Objectives: The purpose of this study was to determine the prevalence of the adverse events of antiretroviral treatment, their impact on mortality and the change in regimens prescribed to children treated at Mildway Centre in Uganda.
Method: A retrospective chart review was performed for children younger than 6 years, treated since the Mildway Centre was opened in 1999. In order to achieve a larger sample, the records of children treated from January 2000 to July 2005 were included in the study. A pre-tested data collection form was used to collate socio-demographic and clinical data of the patients. These included the documented adverse events, causes of death, stage of infection, duration of treatment, regimen prescribed, year of enrolment into the treatment program, as well as whether or not they were still alive. Descriptive statistics were used in the analysis of data.
Results: Of the 179 children, the majority were males and had a median age of 4 years. The majority (58.8%) of children had suffered from severe immune depression since they met the WHO clinical stage III and IV, 73.8% had a baseline CD4T of less than 15%. Four regimens were prescribed to the children. The most common was a regimen containing zidovudine, lamivudine, and nevirapine (34.6%), followed by a regimen containing stavudine, lamivudine, and nevirapine (27.9%). Eleven children (6.1%) had their regimen changed, of which six (54.5%) were due to adverse events. The prevalence of adverse events was 8%; of the 14 documented adverse events, the most common were severe anaemia (3), vomiting (3), and skin rashes (3). After 12 months on treatment, 8% of the patients had died. The most common causes of death were infectious diseases (28.6%), severe anaemia (21.4%), and severe dehydration (21.4%).
Conclusion: The prevalence of adverse events was 8%; they were responsible for 54.5% of regimen changes and 21.4% of deaths in children treated at the study site. These findings suggest the need for incorporating pharmacovigilance practices into the provision of antiretroviral treatment.
How to cite this article: Malangu N, Karamagi Y. Impact of adverse events of antiretroviral treatment on regimen change and mortality in Ugandan children. Afr J Prm Health Care Fam Med. 2010;2(1), Art. #109, 4 pages. DOI: 10.4102/phcfm.v2i1.109
References
Bracher L, Valerius N, Rosenfeldt V, Herlin T, Fisker N, Nielsen H, et al. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark. Scand J Infect Dis 2007; 39:799–804.
De Baets AJ, Bulterys M, Abrams EJ, Kankassa C, Pazvakavambwa IE. Care and treatment of HIV-infected children in Africa: Issues and challenges at the district hospital level. Pediatr Infect Dis J. 2007;26(2):163–173.
Nabukeera-Barungi N, Kalyesubula I, Kekitiinwa A, Byakika-Tusiime J, Musoke P. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop Paediatr 2007;27:123–131.
Ble C, Floridia M, Muhale C, et al. Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania. Acta Paediatr 2007; 96:1090–1094.
Bong CN, Yu JK, Chiang HC, Huang WL, Hsieh TC, Schouten EJ, et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. AIDS 2007;21:1805–1810.
Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, et al. Highly active antiretroviral therapies among HIV-1 infected children in Abidjan, Côte d’Ivoire. AIDS 2004;18:1905–1913.
Marazzi MC, Germano P, Liotta G, Buonomo E, Guidotti G, Palombi L. Pediatric highly active antiretroviral therapy in Mozambique: An integrated model of care. Minerva Pediatr 2006;58:483–490.
Eley B. Addressing the paediatric HIV epidemic: A perspective from the Western Cape Region of South Africa. Trans R Soc Trop Med Hyg. 2006;100:19–22.
Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25:420–426.
Barry G, Coovadia A, Marais B, Malan E, Moultrie H. Analysis of HIV-infected infants under 1 year starting antiretroviral treatment at the coronation paediatric HIV clinic in Coronationville, Johannesburg. Proceedings of the XVI International AIDS Conference [abstract MOPE0233];2006 Aug 13–18; Toronto, Canada.
O’Brien DP, Sauvageot D, Olson D, et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007;44:1245–1248.
Musoke MN, Morelli E, Atai B, Michelin E, Lain MG, Marinello S, et al. Efficacy of HAART in Ugandan HIV-infected children. Proceedings of the XVI International Aids Conference [abstract MOPE026]; 2006 Aug 13–18; Toronto, Canada.
Finkbeiner T, Luyirika E, Nabiddo L, Shinde S, Kilule E, Kasule K, et al. Antiretroviral therapy for HIV-infected children in Uganda, 2004–2005 [abstract WEPE0111]. Proceedings of the XVI International AIDS Conference; 2006 Aug 13–18; Toronto, Canada.
Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311–317.
Carter S, Katyal M, Austin J, Abrams E. Age and CD4 percentage at ART initiation: Relationship to CD4 response over time among children enrolled in MTCT-plus initiative sites [abstract 730]. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles, USA.
Penda I. [Therapeutic strategies for children with HIV infectious risks and infected in a country with limited medical resources]. Les defis de la prise en charge des enfants exposes ou infectes par le VIH dans les pays a resources limitees. J Antibiotiques [serial online]. 2009 [cited 2009 Mar 27]; 11(3):158–163. French. [doi:10.1016/j.antib.2009.02.002]. Available from: http://www.em.consulte.com/article/224551
Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, Otieno PA, Bosire R, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J. 2004;23:536–543.
Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
Full Text: PDF (249 KB) HTML XML
